What Is the Role of EGFR TKIs in Stage III NSCLC?

Previous research showed that gefitinib can improve DFS in certain NSCLC patients, raising the possibility that EGFR-targeted TKIs could be beneficial in the neoadjuvant setting.

Source: CancerNetwork - November 8, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news